8-K: Mangoceuticals Secures $116K in Unit Offering, Amends $500K Convertible Note, and Enters Key Marketing Agreement

Mangoceuticals, Inc. announced a series of strategic financial and operational agreements, including a unit offering that raised $116,249, an amendment to a $500,000 convertible promissory note, and a new digital marketing services agreement.

Summary

• Mangoceuticals, Inc. completed a unit offering on May 23, 2025, selling 70,454 units at $1.65 per unit, raising an aggregate of $116,249.
• Each unit in the offering consisted of one share of common stock and one half of one warrant to purchase one share of common stock, resulting in the issuance of 70,454 common shares and warrants to purchase 35,227 shares.
• The Investor Warrants have an exercise price of $3.00 per share, a term through May 23, 2028, and are cash-only exercise rights.
• The company amended and restated a $500,000 promissory note with Indigo Capital LP, originally dated April 15, 2025, into an Amended and Restated Convertible Promissory Note (A&R Note) effective May 27, 2025.
• The A&R Note allows Indigo Capital LP to convert principal and accrued interest into common stock at a conversion price of $1.50 per share, removing the prior mandatory prepayment requirement.
• In connection with the A&R Note, Mangoceuticals granted Indigo Capital LP warrants to purchase 275,482 shares of common stock (Holder Warrants) with an exercise price of $1.815 per share and a term through May 27, 2028.
• The company entered into a 36-month Terms of Service Agreement with Levo Healthcare Consulting, Inc. for digital marketing and advertising services, commencing June 1, 2025.
• As consideration for the marketing services, Mangoceuticals issued 120,000 restricted common shares to Levo, vesting at 10,000 shares per month.
• The agreement with Levo also includes monthly media buying fees between $25,000 and $35,000 (increasing over time), with Levo receiving 5% to 3% of this fee, plus 4% of gross revenue generated by its services.
• All equity issuances (shares, warrants, and the convertible note) were made under exemptions from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, primarily to accredited investors without general solicitation.
• Maximum shares issuable upon full exercise/conversion are 35,227 from Investor Warrants, 275,482 from Holder Warrants, and 333,333 from the A&R Note principal (excluding accrued interest).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there is significant potential for dilution from the various equity instruments, the company successfully secured additional capital and converted a portion of its debt into a more flexible convertible structure. Furthermore, the establishment of a long-term, exclusive marketing agreement is a crucial step for business growth and market penetration, indicating proactive management in securing operational necessities.

Positives

• The unit offering successfully raised $116,249 in capital, providing immediate funds for the company's operations.
• The amendment to the promissory note provides the company with greater financial flexibility by removing the mandatory prepayment requirement upon a 'Qualified Funding' event.
• Securing a 36-month digital marketing and advertising services agreement with Levo Healthcare Consulting, Inc. is a positive step for business development and market reach.
• The ability for the convertible note holder to convert debt into equity at a fixed price of $1.50 per share could reduce the company's cash interest payment obligations in the future.
• The beneficial ownership limitations (4.999%, adjustable to 9.999%) on warrant exercises and note conversions help prevent immediate excessive concentration of ownership by any single holder.

Negatives

• The issuance of common stock and warrants in the unit offering, along with the convertible note and additional warrants, will result in significant dilution for existing shareholders.
• The promissory note carries a high interest rate of 18% per annum, which could be a substantial financial burden if not converted.
• The marketing agreement with Levo includes a revenue share of 4% of gross revenue generated by services, which could impact profitability as sales grow.
• The company is required to exclusively use Levo for marketing, creative, development, lifestyle, and analytics during the 36-month term, limiting flexibility in choosing other service providers.

Risks

• The securities issued (shares, warrants, convertible note) are restricted and have not been registered under the Securities Act of 1933, limiting their transferability and liquidity for holders.
• There may not be a public market for the newly issued securities, and investors may have to hold them indefinitely.
• The company's ability to accelerate the expiration of Investor Warrants is contingent on its common stock VWAP reaching or exceeding $3.00 for five consecutive trading days, which is not guaranteed.
• The beneficial ownership limitations (4.999% or 9.999%) may restrict the ability of large investors to fully exercise their warrants or convert their notes immediately, potentially impacting their investment strategy.
• The company's reliance on a single marketing firm (Levo) for an exclusive 36-month term could pose a risk if Levo's services do not meet expectations or if the relationship sours.

Future Outlook

The company has secured funding and a long-term marketing partnership, indicating a focus on business development and market expansion. The convertible note provides flexibility for future capital structure management, potentially reducing cash outflows if converted to equity. The marketing agreement is set to begin on June 1, 2025, for a 36-month term, suggesting sustained marketing efforts.

Management Comments

• The company's CEO, Jacob D. Cohen, signed the 8-K filing, indicating management's formal acknowledgment and approval of these strategic financial and operational agreements.
• The agreements reflect management's efforts to secure capital and enhance marketing capabilities, crucial for the company's growth trajectory.

Industry Context

This filing reflects a common strategy for smaller public companies, particularly those in growth phases, to raise capital through private placements and convertible debt, often coupled with strategic partnerships for market penetration. The use of warrants and convertible notes is typical for companies seeking to balance immediate funding needs with future equity considerations. The high interest rate on the convertible note suggests a higher risk profile or limited access to traditional debt financing, common for emerging companies. The digital marketing agreement is a standard operational move to expand reach in a competitive market.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The Amended and Restated Convertible Promissory Note and associated Holder Warrants were issued to Indigo Capital LP, which is a significant financial partner for the company.
• A Terms of Service Agreement was entered into with Levo Healthcare Consulting, Inc. for digital marketing services, involving equity compensation and ongoing fees.

Stakeholder Impact

• **Shareholders:** Experience dilution from the issuance of new common stock and the potential exercise/conversion of warrants and the convertible note. However, the capital raised and marketing efforts could lead to long-term value creation.
• **Creditors (Indigo Capital LP):** The amendment to the promissory note provides flexibility by allowing conversion to equity, potentially reducing the company's debt burden, but also shifts their position from pure debt to a hybrid debt-equity instrument.
• **Employees:** The capital raise and strategic marketing agreement could provide greater stability and growth opportunities for the company, potentially benefiting employees through job security and future expansion.
• **Customers:** The digital marketing efforts are intended to expand the company's reach and potentially improve customer acquisition and engagement.
• **Suppliers/Service Providers (Levo Healthcare Consulting, Inc.):** Levo benefits from a long-term, exclusive contract, including equity compensation and ongoing fees, securing a significant revenue stream.

Next Steps

• Digital marketing and advertising services with Levo Healthcare Consulting, Inc. are scheduled to commence on June 1, 2025, for a 36-month term.
• Potential future exercises of Investor Warrants (exercise price $3.00) and Holder Warrants (exercise price $1.815) through May 2028.
• Potential conversion of the $500,000 Amended and Restated Convertible Promissory Note by Indigo Capital LP into common stock at $1.50 per share.

Key Dates

Recommendation

Keywords

Mangoceuticals, MGRX, SEC Filing, 8-K, Capital Raise, Unit Offering, Common Stock, Warrants, Convertible Promissory Note, Debt Financing, Equity Financing, Digital Marketing, Accredited Investors, Securities Act Exemption, Dilution, Corporate Governance